3
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares are trading higher Monday following news that the U.S. Food and Drug Administration has concluded its inspection of a site involved in the company’s Phase 3 TRANQUILITY II trial.
What To Know: The trial evaluates BXCL501 for the acute treatment of agitation associated with Alzheimer’s dementia. The FDA released an Establishment Inspection Report and designated the site …
